News & Media

MEDIAN Technologies signs a new contract in the field of lung cancer with a top-five pharma company

11 May 2011, Sophia Antipolis, France

MEDIAN Technologies, the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, today announced that it had signed a new contract with a top-five pharma company, following on from an initial contract in 2010.

The new contract covers a pilot study performed as part of a lung cancer trial. This study will investigate the use of an advanced imaging biomarker to evaluate the treatment response (tumor volume, in this case).

“This new collaboration will enable us to study the value of tumor volume as a treatment response criterion. There are several possible advantages. Firstly, the use of tumor volume could decrease variability during image interpretation. Secondly, the change over time in tumor volume may be better correlated with the patients’ survival rate. Thirdly and lastly, tumor volume may show up an earlier treatment response, emphasized MEDIAN’s Chairman and CEO Fredrik Brag. “Innovations in image interpretation are playing an ever more significant role in the cancer drug development process. The signature of this new contract confirms the validity of our approach”, he added.

A number of cancer centers of excellence in the USA, EMEA and Australasia are involved in the study.

MEDIAN Technologies has ISO 13485 certification – the internationally recognized quality standard for the medical device industry. The company’s LMSs gained FDA approval in 2007 and have a class IIa CE mark. The systems are used by key opinion leaders in over 100 centers in Europe, the USA and, most recently, Australia.

Cancer is now the world’s leading cause of mortality, with 12.4 million new cases per year and 7.6 million deaths per year. These figures are set to double by 20301. Imaging forms part of the medical technologies used in the diagnosis and follow-up of treated patients. However, standard methods for image interpretation do not enable the optimal detection of lesions and their quantitative, objective monitoring over time.

MEDIAN Technologies offers the pharmaceutical industry and the medical world a number of integrated LMSs which help interpret medical images and thus improve the diagnosis and follow-up of cancer patients. The LMS software automatically quantifies the lesions and allows the flexible, effective management of lesion-related information. In combination with high levels of automation and standardization, the LMS uses biomarker identification to assist with lesion detection, interpretation, quantification and monitoring over time.

The company’s solutions represent a true breakthrough in imaging-based medicine by enabling a paradigm shift from the subjective evaluation of medical images (biased by variability in lesion interpretation, selection and response tracking) to quantitative, objective, optimized interpretation.

About Lesion Management Solutions

Lesion Management Solutions detect, evaluate and follow-up lesions identified in computed tomography (CT) scans. The LMS performs a number of measurements automatically (such as lesion diameter, volume and density); these parameters are used in both routine clinical practice and during clinical trials to evaluate patient responses to existing cancer therapies or to cancer drug candidates.

Lesion Management Solutions are compatible with all types of CT scanner. They can be integrated into heterogeneous IT environments and easily deployed at sites with very diverse equipment and software configurations.

The MEDIAN Technologies LMSs are “software as a service” (SaaS) products; they are web-based, fully distributed (with cloud computing) and available anywhere in the world.

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”

Contacts

MEDIAN Technologies

Fredrik Brag
CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66
median@alizerp.com